Patents Assigned to Taipei Medical University
  • Patent number: 10450545
    Abstract: This invention relates to microfluidic chips for and their applications in acquiring sperms with high velocity and/or motility. The microfluidic chip comprises an inlet region, a first flow channel, a divergent channel, an optional block structure with rounded corners and one or more outlet region(s). The invention mimics sperm activation process in body and designs a microfluidic chip mimicking the activation process so that higher amount of populations and/or subpopulations of sperms with high motility can be acquired.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: October 22, 2019
    Assignees: NATIONAL TSING HUA UNIVERSITY, TAIPEI MEDICAL UNIVERSITY
    Inventors: Richard Li-Chern Pan, Fan-Gang Tseng, Jen-Kuei Wu, Peng-Chun Chen
  • Patent number: 10308596
    Abstract: Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: June 4, 2019
    Assignees: CITY OF HOPE, TAIPEI MEDICAL UNIVERSITY, ACADEMIA SINICA
    Inventors: Ya-Huei Kuo, Wei-Jan Huang, Chung-I Chang
  • Publication number: 20190153544
    Abstract: Disclosed herein are various methods for assessing the presence of gynecologic neoplasm or the malignancy of the gynecologic neoplasm, based on the hypermethylation of one or more marker genes.
    Type: Application
    Filed: July 28, 2017
    Publication date: May 23, 2019
    Applicant: TAIPEI MEDICAL UNIVERSITY
    Inventor: Hung-Cheng LAI
  • Patent number: 10246455
    Abstract: Fused bicycle indol, indoline, azoindole, or azoindoline compounds of Formula (I) set forth herein. Also disclosed are pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing the same. Further disclosed is a method for treating cancer, e.g., glioma, prostate cancer, and colorectal cancer, with these compounds.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: April 2, 2019
    Assignees: Taipei Medical University, National Health Research Institutes
    Inventors: Jing-Ping Liou, Jang-Yang Chang, Jia-Yi Wang, Yun Yen
  • Patent number: 10238701
    Abstract: The invention provides a water extract of Yan-Sheng-Yin (YSY), a Chinese natural dietary supplement for treatment and/or prevention of hyperlipidemia, atherogenesis and obesity, comprised entirely of natural foods and a preparation comprising the same.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 26, 2019
    Assignee: Taipei Medical University
    Inventors: Chieh-Hsi Wu, Chun-Hsu Pan, Chi-Han Wu
  • Patent number: 10195248
    Abstract: Provided is a method for promoting wound healing, which comprises: administering a haptoglobin subunit to a subject in need thereof. Also provided is a method for promoting wound healing, which comprises: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: February 5, 2019
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Tsai-Mu Cheng, Che-Chang Chang, TH Alexander Wu
  • Patent number: 10195238
    Abstract: The present invention provides a composition for inhibiting renal cancer cell growth and enhancing kidney function. This composition is constituted of water-soluble base material, plasticity-increasing base material, Antrodia camphorata extract, Ganoderma lucidum extract, and auxiliary enzyme. Differing from the conventional therapeutics treating the glomerulonephritis by administering high-dosage steroid for 1-4 months, the renal function of a patient suffering with serious kidney failure can be obviously enhanced after administering this composition of 7 mg/day/kg to the patient for 20 days. Moreover, because the cell biological experiments have proved that the of the present invention possess the functionality to inhibit renal cancer cell growth, this novel composition can indeed be used with chemotherapy drugs clinically, so as to solve the issue that the chemotherapy drugs cannot effectively inhibit the renal cancer cell growth.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: February 5, 2019
    Assignees: TAIWAN INDIGENA BOTANICA CO., LTD., TAIPEI MEDICAL UNIVERSITY
    Inventors: Cheng-Jeng Tai, Yeu-Ching Shi, Ching-Hua Su
  • Patent number: 10188700
    Abstract: Provided is a method for promotion of angiogenesis, comprising: administering a haptoglobin subunit to a subject in need thereof. Also provided is a method for treating a disease related to defective angiogenesis, comprising: administering a haptoglobin subunit to a subject in need thereof. Further provided is a method for promotion of angiogenesis, comprising: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3. Additionally provided is a method for treating a disease related to defective angiogenesis, comprising: administering a modified haptoglobin subunit to a subject in need thereof, the modified haptoglobin subunit comprising an amino acid sequence selected from one of SEQ ID NOs: 1-3.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: January 29, 2019
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Tsai-Mu Cheng, Che-Chang Chang
  • Publication number: 20190016743
    Abstract: The invention relates to compounds for inhibiting a cancer cell or a virus. Particularly, the invention provides compounds for inhibiting, treating and/or preventing cancer and Zika virus.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 17, 2019
    Applicant: Taipei Medical University
    Inventors: Yun YEN, Jing-Ping LIOU, Yun-Ru LIU
  • Patent number: 10131716
    Abstract: The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: November 20, 2018
    Assignees: Taiwan Indigena Botanica Co., Ltd., Taipei Medical University
    Inventors: Cheng-Jeng Tai, Yeu-Ching Shi, Fang-Mo Chang, Ching-Hua Su
  • Publication number: 20180325845
    Abstract: The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Application
    Filed: November 16, 2016
    Publication date: November 15, 2018
    Applicant: Taipei Medical University
    Inventors: Yun YEN, Jing-ping LIOU, Chien Huang LIN
  • Publication number: 20180243264
    Abstract: The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
    Type: Application
    Filed: October 27, 2015
    Publication date: August 30, 2018
    Applicant: Taipei Medical University
    Inventors: Chien Huang LIN, Jing Ping LIOU, Shiou Lin PAN, Che-Ming TENG
  • Patent number: 9956202
    Abstract: The present invention relates to novel use of indolyl and indolinyl hydroxamates. Particularly, the invention relates to use of indolyl and indolinyl hydroxamates in the manufacturing a medicament or a pharmaceutical composition for treating a ischemic and hemorrhagic stroke, spinal cord injury, cranial nerve injury, peripheral nerve injury and a neurodegenerative disorder or cognitive deficit.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: May 1, 2018
    Assignee: Taipei Medical University
    Inventor: Kuo Sheng Hung
  • Patent number: 9944684
    Abstract: The disclosure provides an antigenic peptide targeting the extracellular, but not the intracellular, form of CETP to reduce the level of LDL (including oxLDL and other derivatives of LDL) and increase the level of HDL. Accordingly, the disclosure provides a CETP vaccine to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity to prevent or treat oxLDL or other LDL derivative-related diseases/symptoms.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: April 17, 2018
    Assignee: Taipei Medical University
    Inventor: Jaulang Hwang
  • Patent number: 9907896
    Abstract: The invention provides an apparatus of treating water to obtain small water cluster, which comprises one or more illumination devices and one or more holders holding metal particles. The invention also provides a method of preparing the small water cluster and the small water cluster prepared from the apparatus or the method.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: March 6, 2018
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventor: Yu-Chuan Liu
  • Patent number: 9758778
    Abstract: The invention uses a highly porous MTAM to immobilize yeast cells for bioethanol fermentation, a first in bioethanol production. The invention also optimizes the conditions to prepare MTAM-immobilized cells and evaluates their potential for batch bioethanol fermentation.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: September 12, 2017
    Assignees: Taipei Medical University, National Taiwan Ocean University
    Inventors: Chien Chung Chen, Hong-Ting Lin
  • Publication number: 20170211067
    Abstract: Aptamers that bind to and inhibit CTLA-4 and uses thereof in enhancing immune activities, and treating cancer and HIV infection are provided.
    Type: Application
    Filed: July 31, 2015
    Publication date: July 27, 2017
    Applicants: Academia Sinica, National Taiwan University, Taipei Medical University
    Inventors: Konan Peck, Pan-Chyr Yang, Yi-Chung Chang, Bo-Tsang Huang, Shauh-Der Yeh
  • Patent number: 9713521
    Abstract: The invention provides a highly aligned and closely packed hollow fiber assembly, wherein the assemblies of fibrous membrane has a width-to-fiber diameter ratio (W/d) larger than 10 and the orientation of the fibers is no larger than +/?10°. Also provided is an electrospinning process for the preparation of the fiber assembly of the invention and its applications.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: July 25, 2017
    Assignee: TAIPEI MEDICAL UNIVERSITY
    Inventors: Chien-Chung Chen, Jen-Chang Yang, Jen-Chieh Lu, Sheng-Yang Lee
  • Patent number: 9649323
    Abstract: The invention provides a method for treating target in need of such a treatments in a subject, comprising (a) administering a liposome containing a photosensitizer and a drug to a subject and (b) irradiating targets at least one time at appropriate time(s). In particular, the irradiation is performed at least two times.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 16, 2017
    Assignees: NATIONAL TAIWAN UNIVERSITY, TAIPEI MEDICAL UNIVERSITY
    Inventors: Chin-Tin Chen, Tsuimin Tsai
  • Patent number: 9598364
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: March 21, 2017
    Assignees: Taipei Medical University, Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng